iCare NSW Workers Compensation Reforms - Medication Risk Governance

Across Australian workers compensation schemes, a clear policy direction is emerging. Regulators and insurers are being pushed toward earlier intervention, better clinical governance, and stronger oversight of factors that prolong claims.

“The reforms prioritise prevention, early intervention and effective return to work.”

Recent NSW Workers Compensation reforms highlight this shift. The reforms aim to stabilise the scheme, improve recovery outcomes, and ensure the system remains sustainable for employers and workers. Much of the discussion has focused on psychological injury claims, eligibility thresholds, and the duration of weekly benefits.

However, one critical factor affecting recovery continues to receive very little systematic oversight - Medication use.

High risk prescribing patterns appear repeatedly across long tail claims. Opioids, benzodiazepines, gabapentinoids, antidepressant stacking, and increasingly medicinal cannabis all influence recovery trajectories. These medications affect cognition, sleep, mood, motivation, and functional capacity. In many cases they contribute directly to secondary psychological conditions and prolonged work incapacity.

The challenge is that most claims teams are not trained to identify medication risk. A list of medications in a claim file does not immediately reveal additive sedation, serotonergic stacking, cumulative central nervous system depression, or prescribing cascades. The risk exists, but it remains largely invisible within traditional claims management processes.

This is where a structured medication governance model becomes essential.

The Detection Problem

AllMeds was developed to address the identification gap.

The system analyses medication data and automatically detects patterns associated with increased claim risk. This includes combinations that increase sedation burden, high risk opioid exposure, escalating prescribing patterns, and medication profiles associated with delayed recovery.

Rather than relying on case managers to identify these issues manually, the system provides a clear risk signal across a portfolio of claims.

This enables insurers to identify high risk medication exposure early in the claim lifecycle.

The Clinical Intervention

Once risk is identified, Independent Med Management provides the clinical oversight.

IMM pharmacists conduct independent medication management reviews focused specifically on recovery outcomes within personal injury claims. The objective is not just medication optimisation from a pharmacist perspective.

The focus is on identifying prescribing patterns that affect: • cognitive function • rehabilitation participation • psychological wellbeing • return to work capacity

Where necessary, pharmacists engage with treating doctors to rationalise prescribing and support safer medication prescribing.

A Structured Governance Workflow

Together, AllMeds and IMM create a structured medication governance framework for insurers.

First, AllMeds identifies claims where medication risk is present by analysing medication profiles and detecting patterns associated with delayed recovery, high sedation burden, drug interactions, and escalating prescribing.

Second, those claims are triaged for clinical review. Treating doctors are notified by the insurer when the system identifies potential medication concerns so prescribing can be reviewed within the existing treatment framework.

Third, IMM pharmacists provide targeted intervention and prescriber engagement where medication changes are required, where doctors may require further support to optimise treatment plans, or where there is reluctance to implement prescribing changes. IMM also provide liability and decision support to claims management teams when assessing whether medications and treatments meet the reasonable and necessary threshold.

The result is earlier oversight of one of the most overlooked drivers of claim complexity and a significant reduction in the development of secondary psychological injury or other conditions associated with high risk medication use.

Insurers can see: • how many claims involve high risk medication exposure • which prescribing patterns are associated with prolonged claims • where early clinical intervention may reduce long term costs • which claims require immediate clinical oversight

This level of visibility has historically been absent from workers compensation systems.

The Strategic Advantage

As workers compensation schemes shift toward earlier risk identification and stronger clinical governance, the absence of medication oversight is becoming increasingly visible.

Medication governance represents one of the largest untapped opportunities to improve recovery outcomes and reduce claim duration.

The insurers who address this gap first will have a significant advantage.

AllMeds and Independent Med Management were built to provide exactly that capability.

Watch the full breakdown from iCare presented by Crystal Fitzgibbon Head of Policy, joins David Huxley (Mobile Engagement Team) here.

Read more about the reforms from SIRA Here.

Changes to the NSW Workers Compensation scheme are set to reshape employer obligations, claims management processes, and premium trajectories across the state. The reforms, passed in late 2025 and early 2026, represent the most significant overhaul of the system in more than a decade.